Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Phytomedicine. 2009 Mar 19;16(5):391–400. doi: 10.1016/j.phymed.2009.02.002

Figure 2.

Figure 2

Mean number of symptoms, signs and laboratory values (with 95% confidence intervals) for pathophysiological grouping by (A) impaired biliary excretion; (B) hepatocellular damage; and (C) systemic effects of liver inflammation, comparing silymarin (solid line) and placebo (dashed line) at each visit (see text for which variables were included in the pathophysiological groupings).